EU approves epilepsy medication of Belgian biopharmaceutical company UCB

The Belgian biopharmaceutical company UCB reported in a press release on Wednesday that the European Commission has approved the marketing of the drug Fintepla. It will be used to treat Lennox-Gastaut syndrome, a severe form of epilepsy in children.

The drug has been approved for use on top of other epilepsy drugs, for children aged 2 years and over. ​ Fintepla, the commercial name for the substance fenfluramine, was already approved in Europe for use in the treatment of Dravet syndrome, another severe form of epilepsy.

The drug was already approved in the United States, an important market for pharma companies, and the United Kingdom for the treatment of one or both forms of epilepsy.

Next to epilepsy medication, UCB also produces drugs that treat Crohn's disease, Parkinson's disease and various allergies.



Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.


Belga News Agency delivers dependable, rapid and high-quality information 24 hours a day, 7 days a week, from Belgium and abroad to all Belgian media. The information covers all sectors, from politics, economics and finance to social affairs, sports and culture, not to mention entertainment and lifestyle.

Every day, our journalists and press photographers produce hundreds of photos and news stories, dozens of online information items, plus audio and video bulletins, all in both national languages. Since the end of March 2022 English has been added as a language.

For public institutions, businesses and various organisations that need reliable information, Belga News Agency also offers a comprehensive range of corporate services to meet all their communication needs.


Arduinkaai 29 1000 Brussels